XOMA
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.
XOMA
Industry:
Biotechnology Developer Platform Health Care Therapeutics
Founded:
1981-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.xoma.com
Total Employee:
51+
Status:
Active
Contact:
510-204-7200
Email Addresses:
[email protected]
Total Funding:
155.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
13Therapeutics
A spin out from the Oregon Health and Science University (OHSU) and has exclusively licensed peptides on a world-wide basis.
Acorda Therapeutics
Acorda Therapeutics began in 1995 as a network of scientists, physicians and business people with a common belief.
Adimab
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Beyond Air
Beyond Air is a biotechnology company that focuses on the development of drugs for the treatment of lung infections.
AlivaMab Discovery Services
AlivaMab Discovery Services provides a platform for discovery and development of human therapeutic antibodies.
Animal Cell Therapies
Animal Cell Therapies engages in the research and development of stem cell treatments for acute and chronic diseases in companion animals.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AxioMx
AxioMx offers antibody discovery and development services for the research and diagnostics marketplace.
Beacon Health Strategies
Beacon Health Strategies is engaged in the development and management of mental health and substance abuse programs for hospitals.
BioMarin Pharmaceutical
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Biosystems International
Biosystems International is a biotechnology company engaged in the development of blood-based diagnostics for cancer and chronic diseases.
Biovest International
Biovest International develops fiber bioreactor systems and instruments to help achieve high cell densities.
Bloxr
BLOXR develops products and technology that provide radiation protection in the healthcare, dental, veterinary and nuclear industry.
CDI Laboratories
The CDI mission is to empower research and development in proteomics with proprietary technologies, making possible.
Cordant Health Solutions
Cordant Health Solutions is a provider of drug testing services to groundbreaking solutions for payers, clinicians, and organizations.
Endologix
Endologix is a developer and manufacturer of minimally invasive treatments for aortic disorders.
Epic-Bio
Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
FibroGen
FibroGen, a research-based biotech firm, uses its expertise CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.
GTx
At GTx, They focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body.
Hardin Scientific
Hardin Scientific offers quality tools for exponential discovery and collaboration of the greatest minds within the Life Science Community.
Ichnos Sciences
Ichnos Sciences provides innovation in medicines that help to discover, research and development of breakthrough therapies in oncology.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
iGEM
iGEM is dedicated to the advancement of synthetic biology and development of open community and collaboration.
ImmunoPrecise Antibodies
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery.
InQ Biosciences
InQ Biosciences provides integrated cell growth and cell analysis systems for research and development in the cell and tissue growth sector.
InterMune
InterMune is focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
Kuehnle Agrosystems
Kuehnle Agrosystems is involved in biotech research and development of plant-based systems for producing biologically active compounds.
LPATH
Lpat focuses on the discovery and development of monoclonal antibodies that target bioactive lipids.
Micreos
Micreos, a Wageningen, The Netherlands-based developer of phage technology for targeted control of bacteria.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Nobilis Health
Nobilis Health strategically partners with physicians in the development and management of ambulatory surgical centers
Philips Respironics
Philips Respironics develops, manufactures, and distributes products for sleep and respiratory markets.
Sensiotec
Sensiotec designs and delivers a non-contact remote vital signs monitoring solution for healthcare providers.
Sentien Biotechnologies
Sentien is a developer of new blood conditioning therapies designed to restore balance to the immune system of critically ill patients.
Trellis Bioscience
Trellis Bioscience is a therapeutic antibody company developing treatments for infectious diseases and oncology indications.
Altimmune
Altimmune focused on the development of products to stimulate robust and durable immune responses for the prevention.
Virtuoso Therapeutics
Virtuoso Therapeutics, Inc. is focused on bi-specific antibody drug discovery and development for oncology indication.
XRpro
XRpro provides HTS services yielding high Z’, with excellent reproducibility— helping you to make critical decisions faster.
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals focuses on the acquisition and development of proprietary products and late-stage pharmaceutical products.
Y-Biologics
Y-Biologics is specialized in antibody drug since its inception has focused on research and development
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Novartis
Novartis investment in Post-IPO Equity - XOMA
Official Site Inspections
http://www.xoma.com Semrush global rank: 4.65 M Semrush visits lastest month: 2.12 K
- Host name: 173-254-35-59.unifiedlayer.com
- IP address: 173.254.35.59
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "XOMA"
About Us – XOMA Royalty
XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to potential milestone and royalty payments associated with pre-commercial …See details»
XOMA - Crunchbase Company Profile & Funding
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a …See details»
Management Team :: XOMA Royalty Corporation (XOMA)
Bradley Sitko has been our Chief Investment Officer since January 2023. Mr. Sitko served as Managing Director, Strategic Finance, at RTW Investments, LP, a global, full life-cycle investment firm in the biopharmaceutical and medical …See details»
XOMA Royalty - LinkedIn
XOMA Royalty | 5,376 followers on LinkedIn. We are a biotechnology royalty aggregator playing a distinctive role to help biotech companies achieve their goals. | XOMA Royalty Corporation is a ...See details»
XOMA Royalty March 2025
Mar 3, 2025 16 THE POWER OF THE XOMA ROYALTY MODEL A Single Transaction1 Can Deliver Significant Value for Shareholders 1. Acquired economics agreement from Affitech SA …See details»
XOMA Names Owen Hughes as Chief Executive Officer ... - XOMA …
Jan 8, 2024 XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential …See details»
CORPORATE PRESENTATION - XOMA
May 5, 2023 Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks …See details»
XOMA Royalty Corporation (XOMA) Stock Price, News, …
Find the latest XOMA Royalty Corporation (XOMA) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
XOMA - Contacts, Employees, Board Members, Advisors & Alumni …
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovationSee details»
Xoma onLine
Xoma ERP en salud, es mucho más que un software de historias clínicas. 100% web, crecen hoy muy respetadas instituciones de salud en Colombia. Xoma. Óptima relación costo-beneficio. …See details»
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial ...
4 days ago XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty …See details»
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial ...
5 days ago Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty …See details»
Royalty Portfolio - XOMA
XOMA Royalty has an expansive portfolio of assets that provides us the right to future potential royalty and milestone payments. These drug candidate assets are being developed by others. …See details»
XOMA Royalty to Present at Investor Conferences in March
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive …See details»
XOMA Acquires Royalty and Milestone Economics to ... - XOMA …
Jun 22, 2023 New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹. EMERYVILLE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- XOMA …See details»
XOMA Expands its Commercial Royalty and Milestone ... - XOMA …
Jan 18, 2024 XOMA provided an $8 million non-dilutive royalty capital solution to Talphera. XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% …See details»
XOMA Royalty Significantly Expands its Royalty and Milestone …
Oct 22, 2024 XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from …See details»
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial ...
4 days ago EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its fourth quarter and …See details»
XOMA Royalty Corporation (XOMA) Latest Stock News
Get the latest XOMA Royalty Corporation (XOMA) stock news and headlines to help you in your trading and investing decisions.See details»
XOMA November 2024
Nov 11, 2024 14 KEY ASSETS IN XOMA PORTFOLIO ASSET COMMERCIAL PARTNER INDICATION STAGE CONSENSUS PEAK SALES 1 ROYALTY % VABYSMO® Roche Wet …See details»